Masimo (NASDAQ:MASI) Reaches New 12-Month High - Time to Buy?

Key Points

• Masimo shares hit a new 52-week high, trading as high as $179.00 and last at $178.69 during mid-day trading.
• Analysts' consensus rating is Hold with a consensus price target of $181.17, reflecting several recent downgrades and only one Buy among nine analyst ratings.
• The company has a market cap of $9.6 billion and a negative P/E (−16.95), while institutional investors own about 85.96% of the stock, including a ~2.33 million-share stake held by T. Rowe Price.

Masimo Corporation (NASDAQ:MASI - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $179.00 and last traded at $178.69, with a volume of 1587310 shares. The stock had previously closed at $178.44.

Analysts Set New Price Targets

MASI has been the topic of several recent research reports. Wells Fargo & Company upgraded Masimo to a "hold" rating in a research report on Wednesday, March 18th. Piper Sandler downgraded Masimo from an "overweight" rating to a "hold" rating and set a $180.00 target price for the company. in a research report on Tuesday, February 17th. BTIG Research cut shares of Masimo from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 18th. Weiss Ratings reissued a "sell (d)" rating on shares of Masimo in a research note on Thursday, January 22nd. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Monday, December 1st. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $181.17.

Masimo Stock Performance

The company has a quick ratio of 1.47, a current ratio of 2.49 and a debt-to-equity ratio of 0.72. The company has a fifty day moving average price of $156.72 and a 200 day moving average price of $147.49. The stock has a market cap of $9.60 billion, a PE ratio of -16.95, a P/E/G ratio of 1.81 and a beta of 1.21.

Institutional Trading of Masimo

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC grew its holdings in shares of Masimo by 1.2% in the fourth quarter. Corient Private Wealth LLC now owns 340,230 shares of the medical equipment provider's stock worth $44,250,000 after purchasing an additional 4,015 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Masimo during the 4th quarter valued at $116,000. Pacer Advisors Inc. boosted its position in Masimo by 21.1% during the 4th quarter. Pacer Advisors Inc. now owns 7,360 shares of the medical equipment provider's stock valued at $957,000 after buying an additional 1,280 shares during the period. Virtu Financial LLC purchased a new stake in Masimo during the 4th quarter valued at $258,000. Finally, T. Rowe Price Investment Management Inc. grew its holdings in Masimo by 9.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,330,158 shares of the medical equipment provider's stock worth $303,061,000 after acquiring an additional 203,395 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

About Masimo

Masimo NASDAQ: MASI is a global medical technology company specializing in noninvasive monitoring solutions. The company's flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo's portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.